You are here: Industry Insights > Takeda

News List

Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation americanpharmaceuticalreview
January 30, 2018
Takeda Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAK-426, Takeda’s purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate.
Takeda/Zinfadel ends late-stage Alzheimer’s study pharmatimes
January 29, 2018
Alzheimer’s disease research has taken another hit with the termination of a Phase III study assessing the effect of diabetes drug pioglitazone on mild cognitive impairment (MCI) in patients with the condition.
Takeda spins off cancer assets to incubated startup fiercebiotech
November 23, 2017
The resulting biotech, Chordia Therapeutics, starts life with multiple oncology drugs, lab space at a Takeda site and funding from the Japanese firm and a VC syndicate.
Takeda spins off cancer assets to incubated startup fiercebiotech
November 23, 2017
A team of ex-Takeda scientists has struck out on its own with cancer assets licensed from the drugmaker
Takeda leverages lung cancer awareness month to highlight ALK variant fiercepharma
November 16, 2017
The digital and social media effort encourages patients, caregivers and healthcare providers to share positive experiences and stories.
Takeda, Lundbeck plan U.S. test for depression app in latest beyond-the-pill foray fiercepharma
November 14, 2017
The pharma has teamed with Lundbeck and Advocate Health Care on a study that uses an app with a “conversational text interface” to track and measure patients’ experience on antidepressant therapies.
Takeda’s dengue vaccine surpasses Sanofi’s in P2 trial pharmafile
November 08, 2017
Sanofi spent more than $1.5 billion and two decades to develop the first ever vaccine for dengue fever, only a few years after approval, however, it looks like it could be beaten, in terms of efficacy, by Takeda’s vaccine candidate.
Takeda and HemoShear partner to discover new treatments for liver diseases pharmaceufical-technology
October 20, 2017
NASH is a serious, chronic liver disease characterised by inflammation and excessive fat accumulation in the liver, which may lead to fibrosis, cirrhosis, liver cancer and eventually liver failure.
New analysis backs use of Takeda’s Entyvio pharmatimes
October 19, 2017
Takeda has presented data from a post-hoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio.
Takeda and Noile-Immune to jointly develop new CAR-T immunotherapies for cancer pharmaceufical-technology
September 06, 2017
Takeda Pharmaceutical has entered a collaboration with Noile-Immune Biotech to develop next-generation chimeric antigen receptor T-cell (CAR-T) therapy for solid tumours.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page